Cellares raises $257M to automate and scale cell therapy manufacturing

What’s the deal? Cellares has raised $257 million in a Series D round to scale automated manufacturing for cell therapies. The round was led by BlackRock and Eclipse, with participation from existing and new investors, and will fund global expansion of its Cell Shuttle platform.

The US-based company builds automated, closed systems designed to industrialise the production of cell therapies, which are currently costly and complex to manufacture at scale.

Why now? Demand for cell and gene therapies is growing as more treatments move towards commercial stages, exposing bottlenecks in manufacturing. Many therapies still rely on bespoke, manual processes that limit volume and drive up costs.

Cellares says its automation platform can cut production time and costs, making therapies more viable for broader patient populations and attractive to pharmaceutical partners.

What could go wrong? Scaling cell therapy manufacturing remains technically challenging, with strict regulatory requirements and little room for error. Automation systems must prove reliable across different therapies, sites, and regulators.

Adoption also depends on biopharma companies changing entrenched manufacturing workflows, which can slow uptake even when the technology is promising.

The signal: The round points to rising investor confidence in life sciences infrastructure rather than individual drug assets. Capital is flowing to platforms that promise to unlock scale across multiple therapies.

Cellares’ raise reflects a broader shift towards industrialisation in biotech, as automation and standardisation become critical to turning advanced therapies into sustainable businesses.

Sources:
Cellares
Fierce Pharma
FinSMEs
Pharmtech
Drug Discovery & Development
BioSpace
StartupRise

J.V.